Migraine Prevention — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for migraine prevention. 70 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
70
Active US patents
66/100
Avg vulnerability
—
Annual revenue covered

Originators in Migraine Prevention

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Janssen 70 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating migraine prevention. Each bar = one year. Y-axis scaled to peak year (36 patents).

36
27
4
28
25
33
5
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Topamax
topiramate
 Janssen 70 66 — 2027-11-16

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9555005 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19

Related